巨噬细胞与肝癌转移及临床预后关系研究

Macrophages relations with liver cancer metastasis and clinical prognosis

目的:研究巨噬细胞与肝癌转移及临床预后的关系。方法:收集行肝癌根治性切除术治疗的肝癌患者90例,采用免疫组化染色法检测组织中巨噬细胞的特异标志物CD68和VEGF的表达,与临床病理参数分析,并研究两者之间的相关性。结果:CD68与VEGF在肝癌组织中的表达显著高于正常肝脏组织(P<0.05);C-D期肝癌组织中的CD68浸润程度显著高于A-B期肝癌组织(P<0.05),存在淋巴转移的肝癌组织中的CD68浸润程度显著高于无淋巴转移的肝癌组织(P<0.05);A-B期肝癌组织中VEGF的表达显著低于C-D期(P<0.05),出现淋巴转移的肝癌组织VEGF的表达显著高于未出现淋巴转移者(P<0.05);肝癌组织中VEGF的阳性表达与CD68的表达呈正相关关系(P<0.05)。结论:巨噬细胞的浸润程度和VEGF的表达水平都与肿瘤转移和临床分期有关,和VEGF表达呈正相关关系,CD68有望成为评估肝癌进展程度的重要指标,也为改善肝癌预后提供了新的靶点。

Objective:To study the relationship between macrophage and metastasis of liver cancer and clinical outcome.Methods:retrospectively collected radical resection of liver cancer treatment of the clinical data of 90 patients with liver cancer,using immunohistochemical staining method to detect macrophages in the tissues of the specific markers of CD68 and the expression of VEGF,and clinical pathological parameters analysis,and study the correlation between the two.Results:the expression of CD68 and VEGF in liver cancer tissue was significantly higher than normal liver tissue(P<0.05);C-D cancer of the liver tissue of CD68 infiltration degree was significantly higher than A-B hepatocellular carcinoma tissue(P<0.05),degree of lymphatic metastasis of liver cancer tissue of CD68 infiltration was significantly higher than without lymph node metastasis of liver cancer tissue(P<0.05);A-B of VEGF expression in liver cancer tissue was significantly lower than phase C-D(P<0.05),in lymphatic metastasis of liver cancer tissue expression of VEGF was significantly higher than without lymph node metastasis(P<0.05);The positive expression of VEGF in liver cancer tissue was positively associated with the expression of CD68(P<0.05).Conclusion:macrophage infiltration degree and the expression of VEGF levels are associated with tumor metastasis and clinical stage,and VEGF expression is positively related to relationship,CD68 is expected to become an important index to evaluate the degree of liver cancer progress,also provide new targets for improving the prognosis of liver cancer.